Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Axsome Therapeutics (AXSM) PT Raised to $130 at RBC Capital
June 5, 2024 6:10 AM EDTRBC Capital analyst Leonid Timashev raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $130.00 (from $127.00) while maintaining a Outperform rating.
The analyst comments "We believe the strength of Auvelity's IP is a major point of sensitivity for AXSM shares given the drug's... More
